Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Up 6.9% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX) is a leading biotechnology company focused on developing innovative treatments for serious diseases.

Why is Vertex Pharmaceuticals Incorporated going up?

VRTX stock is up 6.9% on Jan 31, 2025 17:55

• VRTX stock experienced a strong bullish movement.
• Vertex Pharmaceuticals secured FDA approval for a non-opioid pain treatment and reached a reimbursement agreement with NHS England for its gene therapy, driving positive sentiment.
• The market reacted positively to these advancements in pain management and expanded access to treatments for sickle cell disease, propelling VRTX stock higher.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

Vertex Pharmaceuticals Shares Are Up Today: What's Going On? - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for CASGEVY, expanding access to its gene therapy for sickle cell disease. Vertex Pharmaceuticals Inc.

https://www.benzinga.com/trading-ideas/movers/25/01/43395856/vertex-pharmaceuticals-shares-are-up-today-whats-going-on

This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Everest Group ( NYSE:EG ) , Cargo Therapeutics ( NASDAQ:CRGX )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Kate McShane downgraded the rating for Floor & Decor Holdings, Inc.

https://www.benzinga.com/analyst-ratings/downgrades/25/01/43337319/this-everest-group-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday

Vertex Pharmaceuticals ( VRTX ) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

https://www.zacks.com/stock/news/2405049/vertex-pharmaceuticals-vrtx-stock-slides-as-market-rises-facts-to-know-before-you-trade

Trending Today

Ondo ($ONDO) Crypto Forecast: Down 5.2% Today

Align Technology Inc. ($ALGN) Stock Forecast: Down 5.0% Today

Jito ($JTO) Crypto Forecast: Up 19.4% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 19.7% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 5.3% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 10.6% Today

Alibaba Group Holding Limited ($BABA) Stock Forecast: Up 5.0% Today

Algorand ($ALGO) Crypto Forecast: Up 5.7% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.0% Today

Pinduoduo Inc. ($PDD) Stock Forecast: Up 5.1% Today

Vertex Pharmaceuticals Incorporated Price History

18.11.2024 - VRTX Stock was down 2.3%

• Despite a history of positive performance over the past two decades, VRTX encountered a bearish trend today, potentially linked to profit-taking following a period of consistent growth.
• Comparisons with Bristol Myers Squibb (BMY) regarding value could have affected investor sentiment, leading to a sell-off of VRTX shares.
• General market conditions and specific factors within the sector may have contributed to the bearish movement in VRTX today.
• Investors seem to be reassessing their positions in VRTX amidst recent market shifts and the company's future prospects.

05.10.2024 - VRTX Stock was up 3.6%

• Vertex Pharmaceuticals had a +1% change in its stock price, surpassing the market downturn.
• Positive comments from Jim Cramer about VRTX, emphasizing the company's impactful work, may have influenced investor confidence.
• Expectations for robust Q3 earnings, with a projected EPS of $4.14 and revenues of $2.72 billion, could have bolstered the bullish trend.
• Despite signs of a bearish market, the optimistic outlook from analysts and investors likely overshadowed technical indicators, propelling the stock upwards.

15.10.2024 - VRTX Stock was down 5.1%

• Vertex Pharmaceuticals (VRTX) is a biotechnology company focusing on therapies for serious diseases. Today, the market sentiment was bearish.
• The bearish movement in VRTX today might be linked to a comparison between Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX), leading investors to favor GILD as a better value stock option. This shift in focus could have resulted in a sell-off of VRTX shares.

28.07.2024 - VRTX Stock was up 2.4%

• The bullish movement in VRTX stock today could be attributed to several factors:
• The participation of Vertex Pharmaceuticals in upcoming investor conferences may have sparked investor optimism about potential announcements or developments.
• The long-term outperformance of VRTX in the market could have attracted more investors seeking strong returns.
• The bearish positioning of high-rolling investors may have led to a short squeeze scenario, further driving up the stock price as they covered their positions.

19.11.2024 - VRTX Stock was down 17.1%

• The investigation for potential securities fraud could have caused uncertainty and negative sentiment among investors, leading to the bearish movement in VRTX stock.
• The bullish stance taken by wealthy investors might not have been enough to offset the impact of the securities fraud investigation on the stock.
• Despite outperforming the market over the past 20 years, the current investigation news seems to have overshadowed any positive long-term performance, contributing to the bearish movement in VRTX today.

19.11.2024 - VRTX Stock was down 14.5%

• Wealthy investors have taken a bullish stance on VRTX, as indicated by their recent trades in the options market.
• Despite outperforming the stock market over the past 20 years with an impressive annualized return, VRTX experienced a significant decline in its stock price today.
• The positive movement of the stock market today did not translate into gains for VRTX, as it closed lower than the prior day.
• The comparison between VRTX and Bristol Myers Squibb in terms of value may have influenced investor sentiment towards the stock, contributing to its bearish movement.

19.11.2024 - VRTX Stock was down 10.8%

• Vertex Pharmaceuticals reported less-than-promising Phase 2 results for suzetrigine in treating painful lumbosacral radiculopathy, raising doubts about the drug's effectiveness and market potential.
• Concerns arose among investors following an investigation into securities fraud by Block & Leviton, leading to a decrease in confidence and a sell-off of VRTX shares.
• Despite some positive interest from affluent investors, negative news and legal issues may have dominated sentiment surrounding Vertex Pharmaceuticals.
• The stock's weaker performance compared to the market overall and its performance in relation to peers like Bristol Myers Squibb likely contributed to the downward trend.

31.00.2025 - VRTX Stock was up 5.6%

• VRTX saw a decrease of -0.72% amidst the overall bullish market trend.
• Investor sentiment towards VRTX might have been impacted by a recent downgrade from an Everest Group analyst.
• The altered outlook could have prompted caution among investors, resulting in a slight retreat in the stock's value.
• When trading VRTX, it is important for traders to weigh both analyst evaluations and market patterns.

13.00.2025 - VRTX Stock was down 1.9%

• Vertex Pharmaceuticals (VRTX) encountered a bearish trend attributed to a Death Cross, signaling a downturn as the stock dropped beneath crucial moving averages.
• Clinical trial setbacks and technical sell signals exerted downward pressure on VRTX, resulting in a 15% decrease over the last half-year.
• Despite recent negativity, Vertex Pharmaceuticals has historically surpassed the market, boasting a 20.1% average annual return over 20 years.
• Investor comparisons of VRTX against peers in the Medical Biomedical and Genetics sector, such as Incyte (INCY), potentially influenced the bearish outlook on Vertex Pharmaceuticals today.

05.10.2024 - VRTX Stock was up 5.9%

• The bullish movement in Vertex Pharmaceuticals' stock could be driven by positive sentiment surrounding the upcoming third-quarter earnings report, with Wall Street anticipating robust figures.
• Endorsements of Vertex Pharmaceuticals by market analysts might have contributed to boosting investor confidence in the company's prospects.
• Despite the market facing a decline overall, VRTX demonstrated resilience and potential strength in its underlying fundamentals, leading to notable gains.

31.00.2025 - VRTX Stock was up 6.9%

• VRTX stock experienced a strong bullish movement.
• Vertex Pharmaceuticals secured FDA approval for a non-opioid pain treatment and reached a reimbursement agreement with NHS England for its gene therapy, driving positive sentiment.
• The market reacted positively to these advancements in pain management and expanded access to treatments for sickle cell disease, propelling VRTX stock higher.

02.07.2024 - VRTX Stock was down 2.1%

• The company reported a substantial loss in Q2, surprising many and triggering a bearish market response.
• Despite the setback, Vertex Pharmaceuticals raised its annual revenue forecast due to high demand for its cystic fibrosis treatments, suggesting a positive future outlook.
• The bearish market sentiment following the Q2 loss and missed earnings may have overshadowed the optimistic revenue forecast.
• Concerns about the company's recovery from the Q2 loss could be contributing to today's decline in stock price.